Data From Two Pivotal Trials Of AMRIX, A New Once-Daily Extended-Release Muscle Relaxant, Presented At The American Academy Of Pain Medicine Meeting
"Typically, muscle relaxants are taken multiple times a day, which can make it difficult for some of my patients with acute muscle spasm associated with lower back and neck pain to adhere to their treatment regimen," said Arnold J. Weil, MD, of Non-Surgical Orthopaedics in Atlanta, GA, and the lead investigator in these studies. "With data supporting AMRIX as an effective once-daily treatment, health care professionals now have an easy-to-administer treatment option to offer their patients who are suffering from acute muscle spasm."
The data, which were the basis for the U.S. Food and Drug Administration approval of AMRIX, were pooled from two identical 14-day randomized, double-blind, placebo-controlled, multicenter studies, evaluating a total of 504 adults across four study arms (AMRIX 15 mg, AMRIX 30 mg, placebo, and CIR 10 mg three times daily). These participants had moderate-to-severe muscle spasm of cervical or lumbar origin associated with local pain, tenderness, limitation of motion, and restrictions of daily living. In these studies, patients and physicians assessed how helpful the medication was in the treatment of acute muscle spasm. Primary endpoints of the clinical trials were Patient's Rating of Medication Helpfulness at day four of treatment and Physician's Clinical Global Assessment at day four.
Study results of the Patient's Rating of Medication Helpfulness, a measure of efficacy, showed that a higher proportion of patients (p
Datele din douã studii clinice pivot de AMRIX, Un nou-o datã pe zi, cu eliberare prelungitã musculare Relaxant, prezentate la Academiei Americane de dureri de întâlnire medicina - Data From Two Pivotal Trials Of AMRIX, A New Once-Daily Extended-Release Muscle Relaxant, Presented At The American Academy Of Pain Medicine Meeting - articole medicale engleza - startsanatate